Core Insights - Kailas FUGA athletes achieved significant victories at the Chiang Mai Thailand Major by UTMB World Series, with notable wins in both Men's and Women's 100K categories and a second place in Men's 100M [1][2] Group 1: Performance Highlights - Miguel ARSENIO from Portugal won the Men's 100K with a time of 09:14:20, marking an impressive debut performance [1] - Ha Thi HAU from Vietnam secured victory in the Women's 100K, finishing in 10:43:28 [1][8] - Jiaju ZHAO from China finished second in the Men's 100M with a time of 21:40:09 on a challenging course with 8,100m elevation [1] Group 2: Team Composition and Growth - Over 50 athletes participated, representing the largest number of Kailas FUGA elites and FUGA Mountain Club athletes to date, with representation from multiple countries including China, Portugal, and Vietnam [2][4] - The FUGA Mountain Club has grown from a few runners in 2017 to a global team of over 400, with women making up over 45% of the team in China [4] Group 3: Brand and Product Insights - Kailas FUGA's Powergrip footwear was highlighted for its performance on complex and wet terrain, contributing to the athletes' successes [3] - The Kailas FUGA Ex PRO trail shoes were specifically noted for their excellent grip and stability, enhancing athletes' performance during the race [3] Group 4: Future Aspirations - The global team aims to achieve a similar gender representation ratio as seen in China by 2026 [4] - Kailas FUGA continues to focus on innovation and performance, shaping the trail running industry through partnerships with professional athletes and event organizers [5]

Core Insights - SecureTech Innovations, Inc. is launching its AI-driven construction subsidiary, AI UltraProd, in the U.S. market, focusing on the rapidly growing Accessory Dwelling Unit (ADU) sector [1][2] - The ADU market is projected to grow from approximately $19.6 billion in 2025 to over $43 billion by 2034, addressing a significant housing shortage in the U.S. [2] - AI UltraProd's technology, including proprietary materials and a multi-robot matrix, enables efficient construction, capable of printing vertical wall structures for a 2,000 sq. ft. home in days [3] Company Strategy - SecureTech's executive team identified the ADU sector as a scalable entry point for AI UltraProd's technology, allowing for early revenue generation and performance validation [4] - AI UltraProd generated over $3.7 million in revenue during the three months ending September 30, 2025, and is expected to approach eight-figure revenue by the end of 2025 [4] - The company plans to extend its roadmap beyond ADUs to include medical facilities, disaster relief housing, and smart infrastructure [5] Future Initiatives - SecureTech and AI UltraProd are planning a U.S. "Lighthouse Project" to showcase their AI-integrated construction platform in a live environment [5] - Further details on the Lighthouse Project, including deployment locations and strategic partnerships, will be announced [5] - The company encourages stakeholders interested in AI UltraProd's initiatives to reach out for updates [6]

CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Mondelēz International, Inc. (Nasdaq: MDLZ) today declared a regular quarterly dividend of $0.50 per share of Class A common stock. This dividend is payable on January 14, 2026, to shareholders of record as of the close of business on December 31, 2025. About Mondelēz International Mondelēz International, Inc. (Nasdaq: MDLZ) empowers people to snack right in over 150 countries around the world. With 2024 net revenues of approximately $36.4 ...

TEL AVIV, Israel, Dec. 11, 2025 (GLOBE NEWSWIRE) -- HUB Cyber Security Ltd. (Nasdaq: HUBC) (“HUB” or the “Company”), a global leader in confidential computing and secured data fabric technologies, today announced that it has expanded its long-standing relationship with a major European financial institution, adding new cybersecurity assessment and consultancy services to an existing multi-year engagement. Under the expanded scope, HUB will deliver application security testing, including mobile-application ...

SASKATOON, Saskatchewan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into a non-binding letter of intent (“LOI”) to acquire from an arm’s length vendor (the “Vendor”) the prescription files, patient records, and related operational data (the “Pharmacy Files”) of a pharmacy located in the same community as one of PharmaCorp’s existing PharmaChoice-bannered pharmacies in Western Canada (the “Proposed Acquisiti ...

New York, New York, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oak Hill Advisors (“OHA”), a leading global credit-focused alternative asset manager, announced the final close of OHA Senior Private Lending Fund (“OLEND”), the first vintage of OHA’s dedicated senior private lending strategy. OLEND and its related vehicles have raised $17.7 billion of total available capital across their levered and unlevered offerings, including $8.0 billion of equity commitments. OLEND seeks to capitalize on the growing opportunity ...

Core Insights - Rogers has launched Amazon Luna on its Xfinity platform, enabling cloud gaming without the need for consoles or downloads, catering to the growing gaming market in Canada where over 70% of Canadians engage in video gaming [1][2]. Company Overview - Rogers Communications Inc. is a leading communications and entertainment company in Canada, publicly traded on the Toronto Stock Exchange and the New York Stock Exchange [6]. Product Offering - The integration of Amazon Luna allows Rogers Xfinity customers to access over 100 cloud-based games directly from their devices, with Prime members having access to more than 50 top games including popular titles like Hogwarts Legacy [3][4]. - The gaming experience is enhanced by the ability to use voice commands through the Xfinity remote, and players can utilize any major Bluetooth-enabled controller or the Amazon Luna Controller [4]. User Experience - Rogers Xfinity provides a comprehensive entertainment experience by combining cloud gaming with live TV, on-demand content, and streaming apps in a single interface, leveraging Comcast's Entertainment OS platform [5].

CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA), appears to be gaining increasing attention in the oncology community as emerging clinical results continue to surpass expectations in advanced non-small cell lung cancer (NSCLC). With the therapy’s Phase 2 trial ongoing and a pivotal Phase 3 program initiated this week, ateganosine is being closely watched as one o ...

TORONTO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Galway Metals Inc. (TSXV: GWM) (“Galway” or the “Corporation”) is pleased to announce that it has closed its previously announced non-brokered private placement (the “Private Placement”) consisting of 855,370 units of the Corporation (“Units”) at a price of $0.54 per Unit for aggregate gross proceeds to the Corporation of $461,899.80. Each Unit consists of one common share of the Corporation, and one half of one transferable common share purchase warrant (a “Warran ...

Core Insights - AB Science announced a new publication on MedRxiv detailing the clinical benefits of masitinib for amyotrophic lateral sclerosis (ALS) patients before any complete loss of function [2][3] Group 1: Study Findings - The post-hoc subgroup analysis from the phase 2b/3 AB10015 study shows significant improvement in functional decline measured by the ALSFRS-R score, with a 4.04-point difference favoring masitinib over placebo (p=0.0065) [4][5] - A relative benefit of +20.2% on the CAFS score was observed compared to placebo (p=0.0290), surpassing the +13.8% benefit seen in the primary analysis [5] - Median progression-free survival (PFS) was extended by 9 months (p=0.0057) and median overall survival (OS) increased by 12 months (p=0.0192) compared to placebo, both improvements being more pronounced than those in the primary analysis [5] Group 2: Safety and Patient Population - Safety outcomes improved, with a reduction in serious adverse events from 27.6% to 22.6% in masitinib-treated patients [5] - The subgroup analyzed included patients with a score of at least 1 on all ALSFRS-R items at baseline, representing approximately 85% of the primary analysis population [3][5] Group 3: Future Studies - The findings from this analysis will inform the design of the confirmatory study AB23005, which targets patients prior to any complete loss of function to optimize the benefit-risk balance [2][3] - Study AB23005 is a prospective, multicenter, randomized, double-blind, placebo-controlled trial involving 408 ALS patients, aiming to confirm the efficacy and safety of masitinib [7][8]